– USA, NJ – Legend Biotech Corporation (NASDAQ: LEGN), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced the appointment of its CEO and CFO Dr. Ying Huang to the Board of Directors.
“We are delighted to have Dr. Huang join our Board of Directors. As Legend Biotech’s CEO and CFO, Dr. Huang has been instrumental to Legend Biotech’s progress to date, and his extensive knowledge of Legend Biotech will surely enhance our Board of Directors,” said Board chair, Sally Wang.
About Dr. Ying Huang
Ying Huang, Ph.D., has served as Legend Biotech’s CEO since September 2020 and as its CFO since July 2019. Before joining Legend Biotech, Dr. Huang was a Managing Director and Head of Biotech Equity Research at BofA Securities, Inc. from August 2014 to July 2019, where he led a team of analysts covering more than 30 biotechnology companies including Amgen, Gilead, Celgene, Biogen and others that encompass a wide range of therapeutic areas. Dr. Huang became a biotechnology analyst in 2007 and worked at Wells Fargo (formerly Wachovia), Credit Suisse, Gleacher, and Barclays before joining BofA Securities, Inc. Before his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough (now Merck & Co.) in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of the cardiovascular and central nervous system. He is also the co-author of multiple patents and peer-reviewed publications.
Dr. Huang holds a Ph.D. in Bio-organic Chemistry from Columbia University. Dr. Huang also studied at Columbia Business School and in the Special Class for the Gifted Young at the University of Science and Technology of China.
About Legend Biotech
Legend Biotech is a global, clinical-stage biotechnology company dedicated to treating and one-day curing life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious, and cutting-edge therapeutics for patients worldwide.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
